Ovid Therapeutics Inc. Stock

Equities

OVID

US6904691010

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-29 EDT 5-day change 1st Jan Change
3.34 USD +7.74% Intraday chart for Ovid Therapeutics Inc. +6.03% +3.73%
Sales 2024 * 12.81M 17.51M Sales 2025 * 46.35M 63.33M Capitalization 220M 300M
Net income 2024 * -51M -69.69M Net income 2025 * -23M -31.43M EV / Sales 2024 * 17.1 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.74 x
P/E ratio 2024 *
-4.4 x
P/E ratio 2025 *
-10.7 x
Employees 40
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.03%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Ovid Therapeutics Inc.

1 day+7.74%
1 week+6.03%
Current month+9.51%
1 month+9.51%
3 months-13.02%
6 months+2.14%
Current year+3.73%
More quotes
1 week
2.99
Extreme 2.99
3.36
1 month
2.99
Extreme 2.99
3.36
Current year
2.60
Extreme 2.6
4.10
1 year
2.57
Extreme 2.57
4.14
3 years
1.41
Extreme 1.405
4.80
5 years
1.41
Extreme 1.405
9.40
10 years
1.41
Extreme 1.405
15.93
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 14-03-31
Director of Finance/CFO 55 18-12-31
Chief Tech/Sci/R&D Officer - 23-06-27
Members of the board TitleAgeSince
Director/Board Member 59 17-06-13
Director/Board Member 79 15-11-22
Chief Executive Officer 70 14-03-31
More insiders
Date Price Change Volume
24-04-29 3.34 +7.74% 244,562
24-04-26 3.1 +3.68% 80,529
24-04-25 2.99 -5.08% 112,117
24-04-24 3.15 -1.56% 113,127
24-04-23 3.2 +1.59% 110,579

Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm

More quotes
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.1 USD
Average target price
7.429 USD
Spread / Average Target
+139.63%
Consensus